The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Meningococcal Vaccines Market At The End Of The 2026–2030 Forecast Period?
The meningococcal vaccines market has shown strong expansion in recent years. This market is set to grow from $4.26 billion in 2025 to $4.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. The historical increase can be attributed to factors such as the introduction of meningococcal conjugate vaccines, an uptick in meningitis outbreaks, various government immunization campaigns, increasing pediatric vaccination coverage, and augmented public health funding.
The meningococcal vaccines market is projected to experience substantial expansion in the coming years, reaching a valuation of $6.58 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.1%. This anticipated growth stems from advancements in vaccine technology, the broader reach of global immunization initiatives, heightened awareness of meningococcal disease, strategic alliances and partnerships, and an increase in vaccination efforts targeting adolescents and young adults. Key developments expected during this forecast period include the expansion of pediatric vaccination schemes, the creation of wide-ranging meningococcal vaccines, strengthened government-backed immunization programs, greater public understanding of meningococcal disease prevention, and the proliferation of vaccination campaigns in schools and colleges.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp
What Primary Drivers Are Shaping The Development Of The Meningococcal Vaccines Market?
The rising expenditure on healthcare is anticipated to drive the expansion of the meningococcal vaccine market in the future. Healthcare encompasses establishments such as residential care institutions, nursing facilities, and intermediate care facilities for individuals with mental illnesses or mental retardation. A crucial aspect in debates regarding the value of new vaccinations is the significantly higher cost of contemporary vaccine generations compared to earlier ones, questioning if their advantages warrant the price. Evaluating the full societal and economic advantages of vaccination is emerging as an increasingly significant research focus within the literature concerning vaccination valuation. For example, an article from April 2025 by the American Medical Association, a US professional and lobbying body for doctors and medical students, noted that U.S. health spending grew by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person. This expansion rate notably surpassed the 4.6% increase observed in 2022. Consequently, heightened healthcare expenditure is fueling the expansion of the meningococcal vaccine market.
What Segment Types Make Up The Meningococcal Vaccines Market?
The meningococcal vaccines market covered in this report is segmented –
1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine
2) By Serotype: Men Acwy, Men B/Bc, Men C
3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults
4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels
5) By End user: Hospitals, Research, Academic Institutes
Subsegments:
1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine
2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine
3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines
Which Market Trends Are Creating New Opportunities In The Meningococcal Vaccines Market?
Leading companies in the meningococcal vaccines market are actively developing new vaccines to prevent various serogroups, aiming to enhance their market profitability. These meningococcal vaccines serve as critical preventive measures, designed to protect individuals from infections caused by specific serogroups of the Neisseria meningitidis bacteria. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company, secured approval from FDA for its vaccine PENBRAYA. PENBRAYA is recognized as the most comprehensive U.S.-approved meningococcal vaccine, providing extensive serogroup coverage and safeguarding against groups A, B, C, W, and Y. The FDA approval for PENBRAYA was supported by robust Phase 2 and 3 trial data, which confirmed its non-inferior immunogenicity compared to Trumenba + Menveo across all serogroups, coupled with a favorable safety profile. This development follows Pfizer’s September 2022 announcement, detailing positive outcomes from a Phase 3 trial that evaluated PENBRAYA against existing licensed meningococcal vaccines for safety, tolerability, and immunogenicity.
Who Are The Key Players Driving Competition In The Meningococcal Vaccines Market?
Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S
Read the full meningococcal vaccines market report here:
https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report
How Does The Meningococcal Vaccines Market Perform Across Major Global Regions?
North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Meningococcal Vaccines Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp
Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2026, By The Business Research Company
Meningococcal Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report
Meningococcal Disease Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report
Pneumococcal Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model